Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer
Open Access
- 4 December 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 125 (3), 775-784
- https://doi.org/10.1007/s10549-010-1257-5
Abstract
Adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) have proven highly effective in rapidly proliferating breast cancer (RPBC). It has also been seen that sequential administration of doxorubicin and CMF is superior to their alternation, especially in indolent tumors. In a phase III study, we evaluated whether adjuvant epirubicin (E) followed by CMF is superior to the inverse sequence in RPBC. Patients with node-negative or 1–3 node-positive RPBC (Thymidine Labeling Index > 3% or histological grade 3 or S-phase > 10% or Ki67 > 20%) were randomized to receive E (100 mg/m2 i.v. d1, q21 days for 4 cycles) followed by CMF (600, 40, 600 mg/m2 i.v. d1 and 8, q28 days for 4 cycles) (E → CMF) or CMF followed by E (CMF → E) or CMF for 6 cycles. From November 1997 to December 2004, 1066 patients were enrolled: E → CMF 440, CMF → E 438, and CMF 188. At a median follow-up of 69 months, 5-year OS was 91% (95% CI 88–94) for E → CMF and 93% (95% CI 90–95) for CMF → E, with adjusted hazard ratio of 0.88 (95% CI 0.58–1.35), and DFS was 80% in both arms, with adjusted hazard ratio of 0.99 (95% CI 0.73–1.33, Cox model). Adverse events were similar, apart from a higher rate of neutropenia in the CMF → E arm. No important differences in clinical outcome were observed between the two different sequences, making both a valid option in early breast cancer. Further molecular characterization of the tumors might help to identify subgroups achieving higher benefit from either sequence.Keywords
This publication has 22 references indexed in Scilit:
- Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009Annals Of Oncology, 2009
- Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysisBreast Cancer Research and Treatment, 2007
- Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patientsBritish Journal of Cancer, 2007
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2004
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Changes in biological markers after primary chemotherapy for breast cancersInternational Journal of Cancer, 1995
- Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year resultsJAMA, 1995
- Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: a flow cytometry study on fine needle aspiratesEuropean Journal of Cancer, 1993
- Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170- and 180-kDa isozymesExperimental Cell Research, 1992
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958